致力于分子靶向药物和免疫肿瘤药物研发,及商业创新领域
Includes 91 companies , followed by 3 people
Includes 91 companies , followed by 2 people
Includes 29 companies , followed by 2 people
Includes 68 companies , followed by 1 people
Includes 19 companies
Includes 27 companies